$NPCE
NeuroPace Inc Stock $npce

$npce Overview Financials Valuation SEC Filings Company Website

2022 Q1 Form 10-Q Financial Statement

#000152828722000012 Filed on May 12, 2022

Income Statement

Concept	2022 Q1	2021 Q1
Revenue	$11.37M	$11.22M
YoY Change	1.4%	12.45%
Cost Of Revenue	$3.115M	$2.724M
YoY Change	14.35%	-6.65%
Gross Profit	$8.259M	$8.493M
YoY Change	-2.76%	20.35%
Gross Profit Margin	72.61%	75.72%
Selling, General & Admin	$12.44M	$8.267M
YoY Change	50.53%	7.62%
% of Gross Profit	150.67%	97.34%
Research & Development	$5.577M	$4.100M
YoY Change	36.02%	-15.17%
% of Gross Profit	67.53%	48.28%
Depreciation & Amortization	$100.0K	$100.0K
YoY Change	0.0%	0.0%
% of Gross Profit	1.21%	1.18%
Operating Expenses	$18.02M	$12.37M
YoY Change	45.72%	-1.18%
Operating Profit	-$9.762M	-$3.874M
YoY Change	151.99%	-29.02%
Interest Expense	$1.830M	$1.849M
YoY Change	-1.03%	-38.33%
% of Operating Profit
Other Income/Expense, Net	-$3.000K	-$3.113M
YoY Change	-99.9%	-281.52%
Pretax Income	-$11.46M	-$8.810M
YoY Change	30.09%
Income Tax	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$11.46M	-$8.810M
YoY Change	30.09%	30.69%
Net Earnings / Revenue	-100.76%	-78.54%
Basic Earnings Per Share	-$0.47	-$32.73
Diluted Earnings Per Share	-$0.47	-$32.73
COMMON SHARES
Basic Shares Outstanding	24.31M shares	269.2K shares
Diluted Shares Outstanding	24.31M shares	269.2K shares

Balance Sheet

Concept	2022 Q1	2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$103.2M	$30.53M
YoY Change	237.95%
Cash & Equivalents	$7.489M	$13.84M
Short-Term Investments	$95.69M	$16.69M
Other Short-Term Assets	$2.081M	$1.314M
YoY Change	58.37%
Inventory	$8.103M	$7.042M
Prepaid Expenses
Receivables	$9.061M	$8.202M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$122.4M	$47.09M
YoY Change	159.98%
LONG-TERM ASSETS
Property, Plant & Equipment	$860.0K	$476.0K
YoY Change	80.67%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$21.00K	$23.00K
YoY Change	-8.7%
Total Long-Term Assets	$6.562M	$3.236M
YoY Change	102.78%
TOTAL ASSETS
Total Short-Term Assets	$122.4M	$47.09M
Total Long-Term Assets	$6.562M	$3.236M
Total Assets	$129.0M	$50.32M
YoY Change	156.3%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.228M	$1.484M
YoY Change	50.13%
Accrued Expenses	$6.961M	$5.734M
YoY Change	21.4%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due		$3.590M
YoY Change
Total Short-Term Liabilities	$12.06M	$10.81M
YoY Change	11.56%
LONG-TERM LIABILITIES
Long-Term Debt	$50.12M	$49.56M
YoY Change	1.12%
Other Long-Term Liabilities	$3.987M	$274.0K
YoY Change	1355.11%
Total Long-Term Liabilities	$50.12M	$49.84M
YoY Change	0.56%
TOTAL LIABILITIES
Total Short-Term Liabilities	$12.06M	$10.81M
Total Long-Term Liabilities	$50.12M	$49.84M
Total Liabilities	$66.16M	$65.34M
YoY Change	1.26%
SHAREHOLDERS EQUITY
Retained Earnings	-$435.2M	-$396.5M
YoY Change	9.76%
Common Stock	$24.00K	$0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$62.82M	-$156.4M
YoY Change
Total Liabilities & Shareholders Equity	$129.0M	$50.32M
YoY Change	156.3%

Cashflow Statement

Concept	2022 Q1	2021 Q1
OPERATING ACTIVITIES
Net Income	-$11.46M	-$8.810M
YoY Change	30.09%	30.69%
Depreciation, Depletion And Amortization	$100.0K	$100.0K
YoY Change	0.0%	0.0%
Cash From Operating Activities	-$11.40M	-$5.900M
YoY Change	93.22%	-9.23%
INVESTING ACTIVITIES
Capital Expenditures	$306.0K	$35.00K
YoY Change	774.29%	118.75%
Acquisitions
YoY Change
Other Investing Activities	$0.00	-$5.000M
YoY Change	-100.0%
Cash From Investing Activities	-$306.0K	-$5.035M
YoY Change	-93.92%	969.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$1.000K	-$1.578M
YoY Change	-100.06%	-112.6%
NET CHANGE
Cash From Operating Activities	-$11.40M	-$5.900M
Cash From Investing Activities	-$306.0K	-$5.035M
Cash From Financing Activities	$1.000K	-$1.578M
Net Change In Cash	-$11.70M	-$12.55M
YoY Change	-6.78%	-328.12%
FREE CASH FLOW
Cash From Operating Activities	-$11.40M	-$5.900M
Capital Expenditures	$306.0K	$35.00K
Free Cash Flow	-$11.71M	-$5.935M
YoY Change	97.24%	-8.92%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q1	dei	Amendment Flag AmendmentFlag	false
CY2022Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001528287
CY2022Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2021Q2	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.3846
CY2022Q1	dei	Document Type DocumentType	10-Q
CY2022Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2022Q1	dei	Document Period End Date DocumentPeriodEndDate	2022-03-31
CY2022Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2022Q1	dei	Entity File Number EntityFileNumber	001-40337
CY2022Q1	dei	Local Phone Number LocalPhoneNumber	237-2700
CY2022Q1	dei	City Area Code CityAreaCode	650
CY2022Q1	dei	Entity Registrant Name EntityRegistrantName	NEUROPACE, INC.
CY2022Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	22-3550230
CY2022Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	455 N. Bernardo Avenue
CY2022Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Mountain View
CY2022Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2022Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94043
CY2022Q1	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value per share
CY2022Q1	dei	Trading Symbol TradingSymbol	NPCE
CY2022Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2022Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2022Q1	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2022Q1	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	24605333	shares
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7489000	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	19187000	USD
CY2022Q1	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	95686000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	96397000	USD
CY2022Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	9061000	USD
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	7091000	USD
CY2022Q1	us-gaap	Inventory Net InventoryNet	8103000	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	7822000	USD
CY2022Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2081000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2319000	USD
CY2022Q1	us-gaap	Assets Current AssetsCurrent	122420000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	132816000	USD
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	860000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	603000	USD
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5559000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	0	USD
CY2022Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	122000	USD
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	122000	USD
CY2022Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	21000	USD
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	21000	USD
CY2022Q1	us-gaap	Assets Assets	128982000	USD
CY2021Q4	us-gaap	Assets Assets	133562000	USD
CY2022Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	2228000	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1378000	USD
CY2022Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6961000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7923000	USD
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2868000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	0	USD
CY2022Q1	us-gaap	Liabilities Current LiabilitiesCurrent	12057000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	9301000	USD
CY2022Q1	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	0	USD
CY2021Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	911000	USD
CY2022Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	50115000	USD
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	49847000	USD
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3987000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	USD
CY2022Q1	us-gaap	Liabilities Liabilities	66159000	USD
CY2021Q4	us-gaap	Liabilities Liabilities	60059000	USD
CY2022Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	24477180	shares
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	24477180	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	24452999	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	24452999	shares
CY2022Q1	us-gaap	Common Stock Value CommonStockValue	24000	USD
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	24000	USD
CY2022Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	499013000	USD
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	497522000	USD
CY2022Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-982000	USD
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-272000	USD
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-435232000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-423771000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	62823000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	73503000	USD
CY2022Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	128982000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	133562000	USD
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	11374000	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	11217000	USD
CY2022Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	3115000	USD
CY2021Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2724000	USD
CY2022Q1	us-gaap	Gross Profit GrossProfit	8259000	USD
CY2021Q1	us-gaap	Gross Profit GrossProfit	8493000	USD
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5577000	USD
CY2021Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4100000	USD
CY2022Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	12444000	USD
CY2021Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	8267000	USD
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	18021000	USD
CY2021Q1	us-gaap	Operating Expenses OperatingExpenses	12367000	USD
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-9762000	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-3874000	USD
CY2022Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	134000	USD
CY2021Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	26000	USD
CY2022Q1	us-gaap	Interest Expense InterestExpense	1830000	USD
CY2021Q1	us-gaap	Interest Expense InterestExpense	1849000	USD
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-3000	USD
CY2021Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-3113000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-11461000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-8810000	USD
CY2022Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-710000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	0	USD
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-12171000	USD
CY2021Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-8810000	USD
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.47
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.47
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-32.73
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-32.73
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	24307485	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	24307485	shares
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	269178	shares
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	269178	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	73503000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-11461000	USD
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-710000	USD
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1000	USD
CY2022Q1	npce	Adjustments To Additional Paid In Capital Change In Early Exercise Liability AdjustmentsToAdditionalPaidInCapitalChangeInEarlyExerciseLiability	-2000	USD
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1488000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	62823000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-147832000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-8810000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	4000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	202000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	-156436000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-11461000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-8810000	USD
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1488000	USD
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	202000	USD
CY2022Q1	us-gaap	Depreciation Depreciation	80000	USD
CY2021Q1	us-gaap	Depreciation Depreciation	74000	USD
CY2022Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	67000	USD
CY2021Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	69000	USD
CY2022Q1	npce	Increase Decrease In Non Cash Interest Expense IncreaseDecreaseInNonCashInterestExpense	201000	USD
CY2021Q1	npce	Increase Decrease In Non Cash Interest Expense IncreaseDecreaseInNonCashInterestExpense	217000	USD
CY2021Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	3122000	USD
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	672000	USD
CY2021	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	0	USD
CY2022Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	7500000	USD
CY2021Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	0	USD
CY2022Q1	us-gaap	Inventory Write Down InventoryWriteDown	82000	USD
CY2021Q1	us-gaap	Inventory Write Down InventoryWriteDown	24000	USD
CY2022Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1970000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-194000	USD
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	362000	USD
CY2021Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	157000	USD
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-239000	USD
CY2021Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	135000	USD
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	820000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	536000	USD
CY2022Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-472000	USD
CY2021Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1094000	USD
CY2022Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-777000	USD
CY2021Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	0	USD
CY2022Q1	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	0	USD
CY2021Q1	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	-178000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-11393000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5936000	USD
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	306000	USD
CY2021Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	35000	USD
CY2022Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	0	USD
CY2021Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	5000000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-306000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-5035000	USD
CY2022Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1000	USD
CY2021Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	4000	USD
CY2022Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
CY2021Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1582000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1578000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-11698000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-12549000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	19309000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	26756000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7611000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	14207000	USD
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7489000	USD
CY2021Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	13841000	USD
CY2022Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	122000	USD
CY2021Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	366000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7611000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	14207000	USD
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet	1563000	USD
CY2021Q1	us-gaap	Interest Paid Net InterestPaidNet	1563000	USD
CY2022Q1	npce	Increase Decrease In Accrued Liabilities Early Exercise Of Options IncreaseDecreaseInAccruedLiabilitiesEarlyExerciseOfOptions	-2000	USD
CY2021Q4	npce	Deferred Rent DeferredRent	1400000	USD
CY2022Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	31000	USD
CY2021Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	USD
CY2021Q1	npce	Increase Decrease In Accrued Liabilities Early Exercise Of Options IncreaseDecreaseInAccruedLiabilitiesEarlyExerciseOfOptions	0	USD
CY2022Q1	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	0	USD
CY2021Q1	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	578000	USD
CY2021Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2021Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-435200000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-11400000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5900000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	103200000	USD
CY2022Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of unaudited interim condensed financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the amounts and disclosures reported in the financial statements. The Company uses significant judgment when making estimates related to the valuation of its common stock prior to the IPO, and related stock-based compensation, the valuation of deferred tax assets and related valuation allowances, provision for excess and obsolete inventories, and the valuation of redeemable convertible preferred stock warrant liability. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. </span></div>Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.
CY2022Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Credit Risk, and Other Risks and Uncertainties</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to credit risk consist of cash and cash equivalents, short-term investments and accounts receivable to the extent of the amounts recorded on the balance sheet. The Company’s cash is invested in one major financial institution in the United States. Deposits in this financial institution may exceed federally insured limits. The Company’s cash equivalents are invested in money market funds.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s accounts receivable are due from a variety of health care organizations in the United States. For the three months ended March 31, 2022 and 2021, there were no customers that represented 10% or more of revenue. As of March 31, 2022 and December 31, 2021, no customer represented 10% or more of the Company’s accounts receivable.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to certain risks, including that its devices may not be approved or cleared or continue to be approved or cleared for marketing by governmental authorities or be successfully marketed for expanded indications. There can be no assurance that the Company’s products will achieve widespread adoption in the marketplace, nor can there be any assurance that existing devices or any future devices can be developed or manufactured at an acceptable cost and speed and with appropriate performance characteristics. The Company is also subject to risks common to companies in the medical device industry, including, but not limited to, new technological innovations, dependence on healthcare providers to prescribe initial implants and replacements, dependence upon third-party payors to provide adequate coverage and reimbursement, dependence on key personnel, single-source suppliers and vendors in connection with the manufacture of its products, concentration of Level 4 CECs and epileptologists, obtaining, maintaining, protecting, enforcing, and defending intellectual property rights and proprietary technology, product liability claims, legal proceedings, and compliance with government regulations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s medical devices require approvals or clearances from the U.S. Food and Drug Administration, or the FDA, or international regulatory agencies. In addition, in order to continue the Company’s operations, compliance with various federal and state laws is required. If approvals or clearances were withdrawn by the FDA for the Company’s current products or if such approvals or clearances were denied or delayed for future products, product updates, or expanded indications for use, it would have a material adverse impact on the Company.</span></div>
CY2022Q1	us-gaap	Deferred Costs DeferredCosts	0	USD
CY2021Q4	us-gaap	Deferred Costs DeferredCosts	0	USD
CY2021Q2	npce	Research And Development Arrangement With Federal Government Term ResearchAndDevelopmentArrangementWithFederalGovernmentTerm	P5Y
CY2021Q2	npce	Research And Development Arrangement With Federal Government Total Estimated Cost ResearchAndDevelopmentArrangementWithFederalGovernmentTotalEstimatedCost	9300000	USD
CY2021Q2	npce	Research And Development Arrangement With Federal Government Approved Funding Year1 ResearchAndDevelopmentArrangementWithFederalGovernmentApprovedFundingYear1	800000	USD
CY2022Q1	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	200000	USD
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	6100000	USD
CY2022Q1	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	5632000	USD
CY2022Q1	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	95686000	USD
CY2022Q1	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	101318000	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	16498000	USD
CY2021Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	96397000	USD
CY2021Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	112895000	USD
CY2022Q1	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	0	USD
CY2021Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	0	USD
CY2022Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	96668000	USD
CY2021Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	96702000	USD
CY2022Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	982000	USD
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	305000	USD
CY2022Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	95686000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	96397000	USD
CY2022Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	2297000	USD
CY2021Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	2232000	USD
CY2022Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	1210000	USD
CY2021Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	879000	USD
CY2022Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	4596000	USD
CY2021Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	4711000	USD
CY2022Q1	us-gaap	Inventory Net InventoryNet	8103000	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	7822000	USD
CY2022Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	9397000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	9060000	USD
CY2022Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	8537000	USD
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	8457000	USD
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	860000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	603000	USD
CY2022Q1	us-gaap	Depreciation Depreciation	100000	USD
CY2021Q1	us-gaap	Depreciation Depreciation	100000	USD
CY2022Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	5575000	USD
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	6547000	USD
CY2022Q1	npce	Accrued Inventory Liability Current AccruedInventoryLiabilityCurrent	467000	USD
CY2021Q4	npce	Accrued Inventory Liability Current AccruedInventoryLiabilityCurrent	251000	USD
CY2022Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	140000	USD
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	109000	USD
CY2022Q1	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	0	USD
CY2021Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	490000	USD
CY2022Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	779000	USD
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	526000	USD
CY2022Q1	npce	Accrued And Employee Related Liabilities Current AccruedAndEmployeeRelatedLiabilitiesCurrent	6961000	USD
CY2021Q4	npce	Accrued And Employee Related Liabilities Current AccruedAndEmployeeRelatedLiabilitiesCurrent	7923000	USD
CY2018Q2	npce	Operating Lease Renewal Term OperatingLeaseRenewalTerm	P5Y
CY2020Q2	npce	Operating Lease Percent Rental Payment Deferred OperatingLeasePercentRentalPaymentDeferred	0.500
CY2020Q2	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	300000	USD
CY2020Q4	npce	Operating Lease Deferred Rent Interest Rate Annual Rate OperatingLeaseDeferredRentInterestRateAnnualRate	0.080
CY2021Q2	npce	Number Of Deferred Rent Installments NumberOfDeferredRentInstallments	3	installment
CY2022Q1	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	700000	USD
CY2021Q4	us-gaap	Deferred Rent Credit DeferredRentCredit	1400000	USD
CY2022Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	700000	USD
CY2021Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	3172000	USD
CY2021Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	3267000	USD
CY2021Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	1666000	USD
CY2021Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	8105000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	2394000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	3267000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1666000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	7327000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	472000	USD
CY2022Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	6855000	USD
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2868000	USD
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3987000	USD
CY2022Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y3M18D
CY2022Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.063
CY2022Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	800000	USD
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q1	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	0	USD
CY2022Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	7666517	shares
CY2021Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	6237974	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3038970	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.61
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y9M29D
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	580700	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	8.12
CY2022Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	38635	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.03
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	37319	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	0.06
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3543716	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.56
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y9M10D
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1182725	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	0.84
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P8Y4M2D
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	3543716	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	3.56
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P8Y9M10D
CY2022Q1	npce	Share Based Compensation Arrangement By Share Based Payment Award Options Subject To Repurchase ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSubjectToRepurchase	143156	shares
CY2021Q4	npce	Share Based Compensation Arrangement By Share Based Payment Award Options Subject To Repurchase ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSubjectToRepurchase	174171	shares
CY2021Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent	0.85
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	30689	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	20.53
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1488000	USD
CY2021Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	202000	USD
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1488000	USD
CY2021Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	202000	USD
CY2022Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	27300000	USD
CY2022Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y4M24D
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.47
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2021Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-11461000	USD
CY2021Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-8810000	USD
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	24307485	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	24307485	shares
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	269178	shares
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	269178	shares
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.47
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-32.73
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-32.73
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5644197	shares
CY2021Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	19972634	shares

Files In Submission

Name	View Source	Status
0001528287-22-000012-index-headers.html	Edgar Link	pending
0001528287-22-000012-index.html	Edgar Link	pending
0001528287-22-000012.txt	Edgar Link	pending
0001528287-22-000012-xbrl.zip	Edgar Link	pending
exhibit101-firstamendmentt.htm	Edgar Link	pending
exhibit311-certificationsq.htm	Edgar Link	pending
exhibit312certificationsq1.htm	Edgar Link	pending
exhibit321certificationsq1.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
npce-20220331.htm	Edgar Link	pending
npce-20220331.xsd	Edgar Link	pending
npce-20220331_cal.xml	Edgar Link	unprocessable
npce-20220331_def.xml	Edgar Link	unprocessable
npce-20220331_htm.xml	Edgar Link	completed
npce-20220331_lab.xml	Edgar Link	unprocessable
npce-20220331_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NPCE
NeuroPace Inc Stock $npce

2022 Q1 Form 10-Q Financial Statement

#000152828722000012 Filed on May 12, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NPCE NeuroPace Inc Stock $npce

2022 Q1 Form 10-Q Financial Statement

#000152828722000012 Filed on May 12, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NPCE
NeuroPace Inc Stock $npce